Uses of Vildagliptin

Vildagliptin is used to treat type 2 diabetes with the goal of lowering blood sugar by increasing insulin production in the body.

Vildagliptin 50mg is a product containing the active ingredient Vildagliptin used in the treatment of type 2 diabetes in adults. The drug can be used as monotherapy or in combination with 2-3 other drugs:
Monotherapy is indicated in patients who do not have adequate glycemic control through lifestyle such as diet , exercise, and for those patients who are not suitable for Metformin because of contraindications or intolerance. Vildagliptin can be combined with 3 different drugs by using it in combination with Metformin to increase the therapeutic effect more than using Metformin monotherapy with the maximum dose and still not controlling blood sugar effectively. The same goes for Sulphonylurea (SU) and Thiazolidinedion (TZD). Vildagliptin can be combined with Sulphonylurea and Metformin when these drugs are used alone with a reasonable diet but still cannot bring blood sugar to stable.

Vildagliptin has an important advantage that is necessary for patients with long-term type 2 diabetes, which is to help maintain stable blood glucose levels after eating but without causing excessive hypoglycemia. However, this is a new generation antidiabetic drug and has not been tested for a long time, so it may cause some side effects that cannot be fully controlled. Therefore, users should note the following:
Vildagliptin has no effect as a substitute for insulin in patients with insulin-dependent diabetes, and therefore must not be used in patients with type 1 diabetes or in the treatment of patients with type 1 diabetes. Persistent ketoacidosis in diabetes mellitus. The side effects caused by the drug were mostly mild and transient, and did not require discontinuation of treatment. However, there have been rare cases, such as angioedema, in patients receiving Vildagliptin in combination with an angiotensin-converting enzyme (ACE) inhibitor. In cases of liver dysfunction, including nephrogenic hepatitis, Vildagliptin is not recommended by experts for use in patients with pre-treatment ALT or AST levels 2.5 times higher than those of pre-treatment. with the upper limit of normal. During treatment with Vildagliptin, patients should have liver function tests every 3 months for the first year. If liver enzymes are elevated, liver function tests should be performed every 3 months for the first year, then periodically. If AST or ALT levels continue to rise above or 3 times the upper limit of normal, treatment with Vildagliptin should be discontinued. For patients with renal impairment: Since this disease does not affect the half-life of Vildagliptin, no adjustment is necessary in patients with mild renal impairment. In patients with severe or moderate renal impairment, Vildagliptin 50 mg once daily is recommended. Pregnancy and Lactation: Many studies have been conducted in rats at doses up to 200 times that of humans and have not found abnormalities in fertility or embryo development with Vildagliptin use. On the other hand, there was no evidence of teratogenicity in rabbits. However, these studies are incomplete and should not be used by pregnant women. When it is necessary to use it, the benefits should be weighed against the risks. The information in this article is for reference only. Its use in treatment should be under the direction of a specialist.